1. Home
  2. RCKY vs SLN Comparison

RCKY vs SLN Comparison

Compare RCKY & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Brands Inc.

RCKY

Rocky Brands Inc.

HOLD

Current Price

$44.67

Market Cap

242.9M

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$5.52

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCKY
SLN
Founded
1932
1994
Country
United States
United Kingdom
Employees
N/A
116
Industry
Shoe Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
242.9M
236.2M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
RCKY
SLN
Price
$44.67
$5.52
Analyst Decision
Buy
Buy
Analyst Count
1
6
Target Price
$40.00
$39.67
AVG Volume (30 Days)
41.6K
153.4K
Earning Date
05-27-2026
01-01-0001
Dividend Yield
1.30%
N/A
EPS Growth
7.80
N/A
EPS
2.10
N/A
Revenue
$270,408,000.00
N/A
Revenue This Year
$7.09
N/A
Revenue Next Year
$4.27
N/A
P/E Ratio
$22.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.97
$1.97
52 Week High
$48.70
$7.78

Technical Indicators

Market Signals
Indicator
RCKY
SLN
Relative Strength Index (RSI) 77.99 57.17
Support Level $27.77 $5.07
Resistance Level N/A $6.04
Average True Range (ATR) 1.60 0.41
MACD 1.45 0.13
Stochastic Oscillator 82.32 82.77

Price Performance

Historical Comparison
RCKY
SLN

About RCKY Rocky Brands Inc.

Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: